{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,29]],"date-time":"2026-06-29T03:59:07Z","timestamp":1782705547136,"version":"3.54.5"},"reference-count":29,"publisher":"Public Library of Science (PLoS)","issue":"11","license":[{"start":{"date-parts":[[2016,11,18]],"date-time":"2016-11-18T00:00:00Z","timestamp":1479427200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["www.plosone.org"],"crossmark-restriction":false},"short-container-title":["PLoS ONE"],"DOI":"10.1371\/journal.pone.0166266","type":"journal-article","created":{"date-parts":[[2016,11,18]],"date-time":"2016-11-18T18:36:05Z","timestamp":1479494165000},"page":"e0166266","update-policy":"https:\/\/doi.org\/10.1371\/journal.pone.corrections_policy","source":"Crossref","is-referenced-by-count":45,"title":["PD-L1 Status in Refractory Lymphomas"],"prefix":"10.1371","volume":"11","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-9743-7265","authenticated-orcid":true,"given":"Semir","family":"Vranic","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nilanjan","family":"Ghosh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jeffery","family":"Kimbrough","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nurija","family":"Bilalovic","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ryan","family":"Bender","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David","family":"Arguello","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yvonne","family":"Veloso","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aida","family":"Dizdarevic","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zoran","family":"Gatalica","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"340","published-online":{"date-parts":[[2016,11,18]]},"reference":[{"key":"ref1","first-page":"125","article-title":"Advances in cancer immunology and cancer immunotherapy","volume":"21","author":"C Voena","year":"2016","journal-title":"Discov Med"},{"key":"ref2","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1158\/2326-6066.CIR-15-0279","article-title":"Translating Science into Survival: Report on the Inaugural International Cancer Immunotherapy Conference","volume":"4","author":"VM Hubbard-Lucey","year":"2016","journal-title":"Cancer Immunol Res"},{"key":"ref3","doi-asserted-by":"crossref","first-page":"311","DOI":"10.1056\/NEJMoa1411087","article-title":"PD-1 blockade with nivolumab in relapsed or refractory Hodgkin's lymphoma","volume":"372","author":"SM Ansell","year":"2015","journal-title":"N Engl J Med"},{"key":"ref4","doi-asserted-by":"crossref","first-page":"3462","DOI":"10.1158\/1078-0432.CCR-13-0855","article-title":"PD-L1 expression is characteristic of a subset of aggressive B-cell lymphomas and virus-associated malignancies","volume":"19","author":"BJ Chen","year":"2013","journal-title":"Clin Cancer Res"},{"key":"ref5","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1016\/j.humpath.2016.03.005","article-title":"Evaluation of the diagnostic and prognostic value of PDL1-expression in Hodgkin- and B-cell lymphomas","volume":"54","author":"T Menter","year":"2016","journal-title":"Hum Pathol"},{"key":"ref6","doi-asserted-by":"crossref","first-page":"2690","DOI":"10.1200\/JCO.2016.66.4482","article-title":"PD-L1 and PD-L2 Genetic Alterations Define Classical Hodgkin Lymphoma and Predict Outcome","volume":"34","author":"MG Roemer","year":"2016","journal-title":"J Clin Oncol"},{"key":"ref7","doi-asserted-by":"crossref","first-page":"290","DOI":"10.1182\/blood.V124.21.290.290","article-title":"PD-1 blockade with the monoclonal antibody pembrolizumab (MK-3475) in patients with classical Hodgkin lymphoma after brentuximab vedotin failure: preliminary results from a phase Ib study (KEYNOTE-013)","volume":"124","author":"CH Moskowitz","year":"2014","journal-title":"Blood"},{"key":"ref8","doi-asserted-by":"crossref","first-page":"5064","DOI":"10.1158\/1078-0432.CCR-13-3271","article-title":"Association of PD-1, PD-1 ligands, and other features of the tumor immune microenvironment with response to anti-PD-1 therapy","volume":"20","author":"JM Taube","year":"2014","journal-title":"Clin Cancer Res"},{"key":"ref9","doi-asserted-by":"crossref","first-page":"847","DOI":"10.1158\/1535-7163.MCT-14-0983","article-title":"PD-L1 Expression as a Predictive Biomarker in Cancer Immunotherapy","volume":"14","author":"SP Patel","year":"2015","journal-title":"Mol Cancer Ther"},{"key":"ref10","doi-asserted-by":"crossref","first-page":"2965","DOI":"10.1158\/1055-9965.EPI-14-0654","article-title":"Programmed cell death (PD-1) and its ligand (PD-L1) expression in common cancers and their correlation with molecular cancer type","volume":"23","author":"Z Gatalica","year":"2014","journal-title":"Cancer Epidemiol Biomarkers Prev"},{"key":"ref11","doi-asserted-by":"crossref","first-page":"326","DOI":"10.5858\/arpa.2015-0522-SA","article-title":"Programmed Death Ligand-1 Immunohistochemistry: Friend or Foe?","volume":"140","author":"KM Kerr","year":"2016","journal-title":"Arch Pathol Lab Med"},{"key":"ref12","doi-asserted-by":"crossref","first-page":"88","DOI":"10.1016\/j.critrevonc.2016.02.001","article-title":"PD-L1 expression in cancer patients receiving anti PD-1\/PD-L1 antibodies: A systematic review and meta-analysis","volume":"100","author":"S Gandini","year":"2016","journal-title":"Crit Rev Oncol Hematol"},{"key":"ref13","doi-asserted-by":"crossref","first-page":"e0130142","DOI":"10.1371\/journal.pone.0130142","article-title":"Differential Activity of Nivolumab, Pembrolizumab and MPDL3280A according to the Tumor Expression of Programmed Death-Ligand-1 (PD-L1): Sensitivity Analysis of Trials in Melanoma, Lung and Genitourinary Cancers","volume":"10","author":"L Carbognin","year":"2015","journal-title":"PLoS One"},{"key":"ref14","doi-asserted-by":"crossref","first-page":"2460","DOI":"10.1200\/JCO.2015.64.8931","article-title":"Pembrolizumab in Patients With Advanced Triple-Negative Breast Cancer: Phase Ib KEYNOTE-012 Study","volume":"34","author":"R Nanda","year":"2016","journal-title":"J Clin Oncol"},{"key":"ref15","doi-asserted-by":"crossref","first-page":"626","DOI":"10.1002\/gcc.22365","article-title":"Pan-cancer analysis of copy number changes in programmed death-ligand 1 (PD-L1, CD274)\u2014associations with gene expression, mutational load and survival","volume":"55","author":"J Budczies","year":"2016","journal-title":"Genes Chromosomes Cancer"},{"key":"ref16","doi-asserted-by":"crossref","first-page":"3268","DOI":"10.1182\/blood-2010-05-282780","article-title":"Integrative analysis reveals selective 9p24.1 amplification, increased PD-1 ligand expression, and further induction via JAK2 in nodular sclerosing Hodgkin lymphoma and primary mediastinal large B-cell lymphoma","volume":"116","author":"MR Green","year":"2010","journal-title":"Blood"},{"key":"ref17","doi-asserted-by":"crossref","first-page":"26483","DOI":"10.18632\/oncotarget.4494","article-title":"Genomic amplification of 9p24.1 targeting JAK2, PD-L1, and PD-L2 is enriched in high-risk triple negative breast cancer","volume":"6","author":"MT Barrett","year":"2015","journal-title":"Oncotarget"},{"key":"ref18","doi-asserted-by":"crossref","first-page":"5449","DOI":"10.18632\/oncotarget.3216","article-title":"Prognostic and predictive value of PDL1 expression in breast cancer","volume":"6","author":"R Sabatier","year":"2015","journal-title":"Oncotarget"},{"key":"ref19","doi-asserted-by":"crossref","first-page":"206","DOI":"10.1093\/annonc\/mdv510","article-title":"PD-L1 copy number gain in nonsmall-cell lung cancer defines a new subset of patients for anti PD-L1 therapy","volume":"27","author":"T Goldmann","year":"2016","journal-title":"Ann Oncol"},{"key":"ref20","doi-asserted-by":"crossref","first-page":"62","DOI":"10.1016\/j.jtho.2015.09.010","article-title":"PD-L1 Is Upregulated by Simultaneous Amplification of the PD-L1 and JAK2 Genes in Non-Small Cell Lung Cancer","volume":"11","author":"S Ikeda","year":"2016","journal-title":"J Thorac Oncol"},{"key":"ref21","doi-asserted-by":"crossref","first-page":"3026","DOI":"10.1182\/blood-2015-12-686550","article-title":"Genetic basis of PD-L1 overexpression in diffuse large B-cell lymphomas","volume":"127","author":"K Georgiou","year":"2016","journal-title":"Blood"},{"key":"ref22","doi-asserted-by":"crossref","first-page":"2062","DOI":"10.1182\/blood-2013-10-535443","article-title":"Genomic rearrangements involving programmed death ligands are recurrent in primary mediastinal large B-cell lymphoma","volume":"123","author":"DD Twa","year":"2014","journal-title":"Blood"},{"key":"ref23","author":"H Steven","year":"2008"},{"key":"ref24","doi-asserted-by":"crossref","first-page":"563","DOI":"10.1038\/nature14011","article-title":"Predictive correlates of response to the anti-PD-L1 antibody MPDL3280A in cancer patients","volume":"515","author":"RS Herbst","year":"2014","journal-title":"Nature"},{"key":"ref25","doi-asserted-by":"crossref","first-page":"1081","DOI":"10.1182\/blood-2015-08-662783","article-title":"T-cell defect in diffuse large B-cell lymphomas involves expansion of myeloid-derived suppressor cells","volume":"128","author":"I Azzaoui","year":"2016","journal-title":"Blood"},{"key":"ref26","doi-asserted-by":"crossref","first-page":"e445","DOI":"10.1016\/S2352-3026(15)00150-7","article-title":"Ratios of T-cell immune effectors and checkpoint molecules as prognostic biomarkers in diffuse large B-cell lymphoma: a population-based study","volume":"2","author":"C Keane","year":"2015","journal-title":"Lancet Haematol"},{"key":"ref27","doi-asserted-by":"crossref","first-page":"19819","DOI":"10.18632\/oncotarget.4378","article-title":"Disseminated histiocytoses biomarkers beyond BRAFV600E: Frequent expression of PD-L1","volume":"6","author":"Z Gatalica","year":"2015","journal-title":"Oncotarget"},{"key":"ref28","doi-asserted-by":"crossref","first-page":"1308","DOI":"10.1158\/2326-6066.CIR-15-0116","article-title":"PD-L1 Antibodies to Its Cytoplasmic Domain Most Clearly Delineate Cell Membranes in Immunohistochemical Staining of Tumor Cells","volume":"3","author":"KM Mahoney","year":"2015","journal-title":"Cancer Immunol Res"},{"key":"ref29","doi-asserted-by":"crossref","first-page":"1303","DOI":"10.1158\/2326-6066.CIR-15-0150","article-title":"PD-1 and PD-L1 Expression in Renal Cell Carcinoma with Sarcomatoid Differentiation","volume":"3","author":"RW Joseph","year":"2015","journal-title":"Cancer Immunol Res"}],"container-title":["PLOS ONE"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/dx.plos.org\/10.1371\/journal.pone.0166266","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,9,27]],"date-time":"2020-09-27T11:22:20Z","timestamp":1601205740000},"score":1,"resource":{"primary":{"URL":"https:\/\/dx.plos.org\/10.1371\/journal.pone.0166266"}},"subtitle":[],"editor":[{"given":"Riccardo","family":"Dolcetti","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"editor"}]}],"short-title":[],"issued":{"date-parts":[[2016,11,18]]},"references-count":29,"journal-issue":{"issue":"11","published-online":{"date-parts":[[2016,11,18]]}},"URL":"https:\/\/doi.org\/10.1371\/journal.pone.0166266","relation":{},"ISSN":["1932-6203"],"issn-type":[{"value":"1932-6203","type":"electronic"}],"subject":[],"published":{"date-parts":[[2016,11,18]]}}}